Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32769659.
- Also identified by DOI 10.1097/AOG.0000000000004103.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent evidence supports the use of an early, short course of glucocorticoids in patients with COVID-19 who require mechanical ventilation or oxygen support. As the number of coronavirus disease 2019 (COVID-19) cases continues to increase, the number of pregnant women with the disease is very likely to increase as well. Because pregnant women are at increased risk for hospitalization, intensive care unit admission, and mechanical ventilation support, obstetricians will be facing the dilemma of initiating maternal corticosteroid therapy while weighing its potential adverse effects on the fetus (or neonate if the patient is postpartum and breastfeeding). Our objective is to summarize the current evidence supporting steroid therapy in the management of patients with acute respiratory distress syndrome and COVID-19 and to elaborate on key modifications for the pregnant patient.
Medical subject headings
- Coronavirus Infections
- Critical Care
- Glucocorticoids
- Medication Therapy Management
- Pandemics
- Pneumonia, Viral
- Pregnancy Complications, Infectious